The phase 2a study examined the prophylactic (preventative) arm of ISLA-101 in dengue fever and involved four subjects with a 3:1 randomisation ration of (active treatment to placebo). Phase 2b ...
Special Report: Australian antiviral drug development company Island Pharmaceuticals has kicked off the phase 2b clinical trial of lead drug ISLA-101 in dengue fever with the first subjects ...